With a "cosmetically elegant" topical therapy, Pellepharm Inc. CEO Sanuj Ravindran told BioWorld that his firm is hoping to exploit the upside of hedgehog inhibition demonstrated so well by Erivedge (vismodegib, Roche Holding AG) while avoiding the downside of a systemic therapy with that mechanism of action in basal cell carcinoma (BCC).